Golden
Miragen Therapeutics

Miragen Therapeutics

miRagen is a clinical stage biopharmaceutical company developing innovative microRNA-targeting therapies to improve human health.

miRagen is a publicly traded, biopharmaceutical company based in Boulder, Colorado that was founded in 2007 by Eric N. Nolan. It focuses on discovering and developing microRNA (miRNA) targeting therapies to improve human health. The company's area of focus include hematological malignancies, pathological fibrosis, neuro-degeneration, and cardiovascular disease.

Products

The company's product pipeline consists of three products, Cobomarsen (MRG-106), Remlarsen (MRG-201), and MRG-110.

Cobomarsen

The Cobomarsen program targets miR-155, a micro RNA that has key roles in the differentiation, function, and proliferation of blood and lymph cells. It is being developed to treat patients who suffer from the mycosis fungicides (MF) form of cutaneous T-cell lymphoma (CTCL). It is also being explored as a treatment option for several other blood cancers and certain solid tumors, including diffuse large B-cell lymphoma, acute myeloid leukemia, certain virally induced lymphomas, Down Syndrome associated acute lymphocytic leukemia, and other types of cancer. The drug is in Phase 2 clinical trials for CTCL and in Phase 1 clinical trials for the other types of cancer.

Remlarsen

The Remlarsen program is a treatment for pathological fibrosis. It is a replacement for miRNA-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary, and ocular fibrosis, as well as systemic sclerosis. It is in Phase 2 clinical trials for cutaneous fibrosis while it is in pre-clinical stages for other types of fibrotic indications.

MRG-110

miRagen's third product candidate, MRG-110 targets miR-92a, a microRNA linked to the regulation of blood vessel growth. It is targeted as a treatment for chronic ischemic disorders by increasing blood vessel growth and accelrating the healing process. MRG-110 is being developed under a license and collaboration agreement with Servier, a privately run, French research-based pharmaceutical company. The agreement was formed in 2011.

Funding

Series A

On May 19, 2008 miRagen Therapeutics completed their series A funding round with $8 million in funding from Boulder Ventures and Atlas Ventures. 

Series B

On April 24, 2012 miRagen Therapeutics completed their series B funding round with $20 million in funding from Remeditex Ventures (lead investor), Broadview Ventures, Boulder Ventures, Atlas Ventures, and Amgen Ventures. 

Series C

On February 13, 2017 miRagen Therapeutics completed their series C funding round with $40.7 million in funding from Reneditex Ventures, MRL Ventures Fund, MP Healthcare Venture Management, JAFCO Japan, Fidelity Management and Research Company, Brace Pharma, Boulder Ventures, and Atlas Ventures. 

Timeline

Funding rounds

2 Results
Funding round
Funding round
Funding round amount (USD)
Funding round amount (USD)
Funding type
Funding type
Funding round date
Funding round date
Investment
Investment

People

Name
Role
LinkedIn

Adam Levy

Chief Business Officer



Bruce Booth

Founder



Jason A Leverone

CFO



Jason P. Hafler

Investor



Miles Gerson

Employee



Paul Rubin

Executive VP of Research and Development



Robert Smartt

Investor



Sam Clouse

Employee



Sanjoy Mahanty, PhD

Founder



William S. Marshall

Co-Founder, President, & CEO



Further reading

Title
Author
Link
Type
Date

Miragen Therapeutics to Present New Cobomarsen Phase 1 Clinical Trial Data at the 2018 American Society of Hematology Annual Meeting

Miragen Therapeutics, Inc.

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References